Pholipomycin, a new member of phosphoglycolipid antibiotics. III. Biological properties.
Pholipomycin, a new member of the phosphoglycolipid antibiotics, was primarily active against gram-positive bacteria including clinically isolated resistant bacteria. It differed from other members of the antibiotic family as it also demonstrated activity against gram-negative bacteria. Pholipomycin protected mice from infection with Staphylococcus aureus and was nontoxic to mice having an LD50 (i.v.) of 600 mg/kg. Besides possessing anti-microbiol activity, pholipomycin, when administered orally, appeared to promote growth in chickens and pigs.
D000192:Actinomycetales / Q000187:drug effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001412:Bacillus subtilis / Q000187:drug effects; D002645:Chickens / Q000254:growth & development; D004353:Drug Evaluation, Preclinical; D004755:Enterobacteriaceae / Q000187:drug effects; D005658:Fungi / Q000187:drug effects; D051379:Mice; D008837:Micrococcus / Q000187:drug effects; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013552:Swine / Q000254:growth & development; D015003:Yeasts / Q000187:drug effects
D000900:Anti-Bacterial Agents